Condition: Type 1 Diabetes Mellitus · Sponsor: Mannkind Corporation
INHALE-1st is a Phase 2, single-arm, multi-center, clinical study evaluating the safety and efficacy of Afrezza in combination with subcutaneously-injected basal insulin (BI) for youth 10 to \<18 years old with newly diagnosed stage 3 type 1 diabetes (T1D). The study will also evaluate the effect of an Afrezza plus BI reigmen on participant and parent/legally authorized representative satisfaction. Participants will be followed for 13 weeks during the main phase followed by an optional Extension Phase for participants continuing to use Afrezza in combination with BI for up to 26 weeks.
This description comes directly from the study's public registry record.
Jennifer Pleitez · 818-661-5032 · jpleitez@mannkindcorp.com
Always discuss trial participation with your own doctor first.
| Children's Hospital Los Angeles | Los Angeles, California, United States | Recruiting |
| University of California San Francisco | San Francisco, California, United States | Recruiting |
| Barbara Davis Center for Diabetes Young Adult Clinic | Aurora, Colorado, United States | Recruiting |
| Yale University | New Haven, Connecticut, United States | Recruiting |
| University of Florida | Gainesville, Florida, United States | Recruiting |
| Indiana University | Indianapolis, Indiana, United States | Recruiting |
| Joslin Diabetes Center | Boston, Massachusetts, United States | Recruiting |
| University of Oklahoma Health Sciences Center | Oklahoma City, Oklahoma, United States | Not Yet Recruiting |
| Baylor College of Medicine | Houston, Texas, United States | Recruiting |
| University of Virginia | Charlottesville, Virginia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07224321